Outstanding DD steadyhand.
Early DD on stocks like ONCX, is much more valuable than the comments that follow after the fact.
Cleary Oncolix is expanding research for Prolanta, not just initiating it.
ONCX has a worldwide patent portfolio that includes Europe, the UK, France, Germany etc…
Common sense would dictate that an effort to clear regulatory hurtles internationally, is a good thing for ONCX shareholders.
Thanks for posting.
IMO and FWIW.